Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 11/20 | 0.49 |
| ▸ | CDK9 | P50750 | 11/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14739552 | 0.90 | MAPK11 (0.48) | CCNT1CDK9HSD11B1SLC6A4PTGDR2 | |
| SCHEMBL28800855 | 0.88 | HSD11B1 (0.41) | CCNT1CDK9HSD11B1SLC6A4PTGDR2 | |
| SCHEMBL7707688 | 0.87 | HSD11B1 (0.47) | HSD11B1SLC6A4PTGDR2ALDH1A1MAPK11 | |
| SCHEMBL7712303 | 0.84 | MAPK11 (0.47) | HSD11B1SLC6A4PTGDR2MAPK11MAPK14 | |
| SCHEMBL14739107 | 0.82 | HSD11B1 (0.48) | CCNT1CDK9HSD11B1POLBCNR1 | |
| SCHEMBL7711798 | 0.81 | RHEB (0.39) | CDK9HSD11B1SLC6A4PTGDR2ALDH1A1 | |
| SCHEMBL14738750 | 0.81 | RHEB (0.39) | CDK9HSD11B1SLC6A4PTGDR2ALDH1A1 | |
| SCHEMBL14738748 | 0.81 | RHEB (0.39) | CDK9HSD11B1SLC6A4PTGDR2ALDH1A1 | |
| SCHEMBL7712729 | 0.79 | PDK2 (0.37) | HSD11B1SLC6A4PTGDR2ALDH1A1 | |
| SCHEMBL14738973 | 0.79 | PDK2 (0.37) | HSD11B1SLC6A4PTGDR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059850-A1 | AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059850-A1 | AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2011140164-A1 | AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059850-A1 | AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | FAAH, FAAH2, IDO1 | CCNT1 2182/4885CDK9 977/4885HSD11B1 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.